Experimental and Clinical Psychopharmacology
June 7, 2021
Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al.
53 citations
Psychedelic-assisted psychotherapy (PAP) shows promise for treating substance use disorders, PTSD, depression, and anxiety in randomized, double-blind, placebo-controlled trials, but research has almost exclusively involved White populations in North America and Western Europe, neglecting Black, Indigenous, and People of Color (BIPOC). Ethnoracial differences in the metabolism, safety, and efficacy of psychotropic drugs are known from previous research, yet no studies have directly examined such differences for psychedelic pharmacology. This article argues that failing to include BIPOC in trials limits generalizability and overlooks biological and social factors affecting responses to PAP. It discusses limitations of ethnopsychopharmacology and advocates for expanded funding to address cultural, clinical, and public health needs.
Journal of Psychedelic Studies
July 15, 2021
Zoe W. Jahn, Joel Lopez, Sara de la Salle et al.
36 citations
About 15.9% of the U.S. population over age 12 had used a hallucinogen at least once, and 2.0% had used one in the past year. Lifetime use was most common among non-Hispanic White and multi-racial individuals, while Black/African Americans reported the lowest rates. Past-year use was highest among White and multi-racial groups aged 12–34 and among White individuals aged 35–49. Hispanic individuals showed higher past-year use in the 12–17 age group but lower use in the 26–49 range. Black/African Americans had the lowest past-year use among 12–25 year olds. Adults 50 and older reported the lowest past-year use overall.
Journal of Studies on Alcohol and Drugs
July 1, 2022
Timothy I. Michaels, Lebert Lester, Sara de la Salle et al.
19 citations
Black, Indigenous, and People of Color (BIPOC) are greatly underrepresented in ketamine clinical trials for mood disorders, despite experiencing high rates of such conditions. A review of double-blind, placebo-controlled, randomized ketamine trials from 1993 to 2020 found that among 380 participants, 73.7% were non-Hispanic White, 9.2% Black, 5.0% Hispanic/Latinx, and 0.8% Asian. Higher BIPOC inclusion was negatively correlated with the number of recruitment methods used. The lack of reported demographic information may further underestimate BIPOC participation. These disparities mean reported treatment outcomes may not generalize to all groups, and unequal access to novel treatments worsens health inequities.